ClinicalTrials.gg

Program

gumokimab

Its studies are mostly in Psoriasis · Spondylitis, Ankylosing, led by Akeso.

Furthest: phase 3, since Sep 27, 20236 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso61 open or runningphase 3since Sep 27, 2023Feb 10, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 10, 2022First study: phase 2 study in Spondylitis, AnkylosingFirst studyNCT05467995 · 125 enrolled · China
  2. Jun 29, 2022Phase 1 study in PsoriasisNCT05504317 · 48 enrolled · China
  3. Sep 24, 2023Phase 2 study in PsoriasisNCT06061471 · 454 enrolled · China
  4. Sep 27, 2023Phase 3 study in PsoriasisNCT06066125 · 351 enrolled · China
  5. Mar 1, 2024Phase 3 study in Spondylitis, AnkylosingNCT06378697 · 510 enrolled · China
  6. Apr 21, 2025Phase 1 study in Healthy SubjectsNCT06947109 · 48 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06947109Healthy Subjects · China1Not yet recruitingJan 30, 202648
NCT06378697Spondylitis, Ankylosing · China3CompletedFeb 19, 2025510
NCT06066125Psoriasis · China3CompletedAug 19, 2024351
NCT06061471Psoriasis · China2CompletedDec 11, 2024454
NCT05504317Psoriasis · China1CompletedMar 2, 202148
NCT05467995Spondylitis, Ankylosing · China2CompletedApr 25, 2022125

How it is read

Names in the registry

  • “AK111”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.